Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02951754 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Trial Details
NCT Number NCT02951754
Lead Sponsor Hospital de Clinicas de Porto Alegre
Collaborators: Federal University of Rio Grande do Sul, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordination for the Improvement of Higher Education Personnel
Conditions
(from sponsor)		 Attention Deficit Disorder With Hyperactivity
Related terms Attention Deficit Disorder with Hyperactivity
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov